Nivalis Therapeutics, Inc. (ALPN)
(Delayed Data from NSDQ)
$6.24 USD
-0.08 (-1.27%)
Updated May 3, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[ALPN]
Reports for Purchase
Showing records 101 - 120 ( 156 total )
Industry: Medical - Drugs
ALPN-202''s Future Appears Luminous with First Look at NEON-1
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Evidence Builds for ALPN-303?s Differentiated Profile in B Cell Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
ALPN-202 Makes Its Debut with Promising Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
1Q21 Results; Pipeline Humming Along Nicely; Key Update at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Investor Meetings Solidify Opportunities; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Industry: Medical - Drugs
Q4 Financials; SLE Ph 2 to Initiate Mid-Year; ?202 Data at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Industry: Medical - Drugs
2020 Results; Active Clinical Pipeline Takes Center Stage for Upcoming Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Targeting the Immune System From All Angles; Initiating at Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Q2 Financials; ALPN Well Positioned as NEON Study Continues Enrollment
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R